The Plasma Kallikrein pipeline drugs market research report outlays comprehensive information on the Plasma Kallikrein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Plasma Kallikrein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Ophthalmology, Infectious Disease, and Respiratory which include the indications Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), Angioedema, Diabetic Macular Edema, Diabetic Retinopathy, Coronavirus Disease 2019 (COVID-19), and Acute Respiratory Distress Syndrome. It also reviews key players involved in Plasma Kallikrein targeted therapeutics development with respective active and dormant or discontinued products.
The Plasma Kallikrein pipeline targets constitutes close to 16 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and Preclinical stages are 1, 2, 4, 1, and 8 respectively.
Plasma Kallikrein overview
Plasma Kallikrein (KLKB1) encodes a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. The KLKB1 gene provides instructions for making a protein called prekallikrein and factor XII converts prekallikrein to plasma kallikrein. Plasma kallikrein and factor XII are involved in the early stages of blood clotting.
For a complete picture of Plasma Kallikrein ‘s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
